We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Hypoxia contributes to the aggressive and treatment-resistant phenotype of pancreatic ductaladenocarcinoma.
2
Conclusions: This paper emphasizes the grim prognosis of pancreatic ductaladenocarcinoma.
3
Purpose: To evaluate imaging findings of diffuse pancreatic ductaladenocarcinoma.
4
HG-PanIN mutation profiles were compared with those of their associated invasive pancreatic ductaladenocarcinoma.
5
Methods: We prospectively collected data on the families of patients presenting with pancreatic ductaladenocarcinoma.
1
The findings demonstrate that overexpression of USP28 correlates with a better survival in patients with invasiveductalbreastcarcinoma.
2
We examined CTCF protein expression in 18 invasiveductalbreastcarcinomas using immunohistochemistry.
3
We have examined 301 invasiveductalbreastcarcinomas by this method.
1
Three females presented with invasiveductalcarcinomaofthebreast after treatment for Hodgkin's disease.
2
These results also suggest the prognostic value of pAkt and its importance in the prediction of therapeutic response in invasiveductalcarcinomaofthebreast.
3
Sixteen patients with invasiveductalcarcinomaofthebreast were prospectively included and underwent both, contrast-enhanced breast MRI and (1)H MRS examination of the breast.
4
Conclusions: Histopathologic grading and flow cytometric determination of SPF appear to provide additive prognostic information for patients with early invasiveductalcarcinomasofthebreast.
1
Histological analysis indicated infiltratingductalcarcinoma in all cases.
2
We report on a rare distinctive variant of infiltratingductalcarcinoma characterized by sebaceous differentiation of tumor cells.
3
Fourteen patients who underwent scintimammography and subsequent surgical excisional biopsy that revealed infiltratingductalcarcinoma were enrolled in this study.
1
The aim of this study was to assess the relationship between the degree of MIBI tumor uptake and cadherin expression in infiltratingductalbreastcarcinoma.
Usage of invasive ductal carcinoma in English
1
The tumor showed features of poorly differentiated invasiveductalcarcinoma of clear-cell phenotype.
2
Available data suggest improved outcome for papillary carcinoma as compared to invasiveductalcarcinoma.
3
Histological findings for the lymph node indicated a metastasis of the invasiveductalcarcinoma.
4
Three females presented with invasiveductalcarcinoma of the breast after treatment for Hodgkin's disease.
5
Histopathology confirmed a bifocal invasiveductalcarcinoma.
6
We investigated the incidence of Akt activation in invasiveductalcarcinoma and its correlation with other clinicopathological variables.
7
All recurrences were invasiveductalcarcinoma.
8
Here, we present a case of a patient with both invasiveductalcarcinoma and chronic lymphocytic leukemia in the breast.
9
Methods: Between April 1992 and December 2006, 140 patients underwent a pancreatic resection for invasiveductalcarcinoma.
10
Conclusion: ABCG2 correlated with Her-2 expression, lymph node metastasis and clinical stage in breast invasiveductalcarcinoma.
11
Results: The results showed that ABCG2 was expressed in different intensities and distributions in the tumor cells of the breast invasiveductalcarcinoma.
12
We report an extremely rare case of the colocalization of a tubular adenoma and an invasiveductalcarcinoma occurring in a 55-year-old woman.
13
Results: A total of 991 patients with invasiveductalcarcinoma and 150 patients with invasive lobular carcinoma were identified.
14
These results also suggest the prognostic value of pAkt and its importance in the prediction of therapeutic response in invasiveductalcarcinoma of the breast.
15
The histological boundary was clearly defined between the tubular adenoma and the invasiveductalcarcinoma, and between the tubular adenoma and the surrounding breast tissue.
16
Sixteen patients with invasiveductalcarcinoma of the breast were prospectively included and underwent both, contrast-enhanced breast MRI and (1)H MRS examination of the breast.